Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from October 20, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on January 18, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$54.50 – $56.50Entry zone — fair-value band

$55.66Published — price the day we called it

$64.00Target — the price the thesis aimed for

$62.40Peak — highest point inside the window, not a realized return

$62.33Window close — end-of-window price, context only

What happened

Target reached

Hit or exceeded the predicted growth inside the window.

Peak price

$62.40

peak on January 16, 2026 — not a realized return

Peak gain

+12.1%

peak, from the publication price

Window close

$62.33

end-of-window price, context only

Days to target

—

Window

October 20, 2025 – January 18, 2026

The thesis — published October 20, 2025

Predicted growth

+15%

over the measurement window

Target price

$64.00

the price the thesis aimed for

Entry zone

$54.50 – $56.50

the fair-value band we waited for

Price at publication

$55.66

published October 20, 2025

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk leads in diabetes and weight-loss drugs, and the recent dip looks short term. The FDA now says the Rybelsus pill may help lower heart risk, and Costco is making these medicines easier to get at about $499 per month, which should keep demand strong. Shares look weak after a slide and may steady before turning. Consider buying on down days and watch for the recent average price to start rising over 1-3 months.

Primary drivers

Strong demand for GLP-1 drugs and easier access for more patients
FDA label says Rybelsus may reduce heart risk, boosting doctor confidence
Shares look beaten down and may be due for a short-term bounce
Leader in its field with products and scale that are hard to copy

How it played out

NVO: rose 12.1% but missed the target

Lyra published NVO on 2025-10-20 at 55.66. The thesis called for 15% growth and pointed to Novo Nordisk's diabetes and weight-loss drugs, easier access at about $499 per month, the Rybelsus heart-risk label, and a possible bounce after weakness.

Inside the window, the stock rose but did not finish the job. It peaked at 62.4 on 2026-01-16, with a 12.1% gain, and stayed below the 64 target. It ended at 62.33 on 2026-01-18. The thesis partially played out. It never got there.

What happened during the window

On 2025-12-22, the FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 drug for weight loss. On 2026-01-05, Time reported that the pill had reached pharmacies and that bottles were being produced in four doses.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals